Sirtex Medical Inc. Hosts Dinner Symposium At The 2013 American Hepato-Pancreato-Biliary Association’s Annual Meeting

Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today it will host a dinner symposium during the 2013 American Hepato-Pancreato-Biliary Association’s (AHPBA) Annual Meeting. The educational event will take place Thursday, Feb. 21 from 7–8:30 p.m.at the Eden Roc Renaissance in Miami.

The symposium, titled “Y-90 Selective Internal Radiation Therapy for Colorectal Liver Metastases,” is designed to educate Surgical Oncologists about the latest data and role of SIR-Spheres ® microspheres, the only fully FDA PMA-approved microsphere radiation therapy for the treatment of metastatic colorectal cancer.

Moderated by Roderich Schwarz, M.D., Ph.D., Medical Director, IU Health Goshen Hospital, the event will feature three leading Surgical Oncologists who will discuss the following topics with symposium attendees:
  • “History, Mechanisms, Indications and Safety of Y-90 Therapy” by N. Joseph Espat, M.D., M.S., F.A.C.S., Chairman, Department of Surgery, Roger Williams Medical Center
  • “Clinical Data and Comparative Assessment of Outcomes of Y-90 Therapy” by David Kooby, M.D., F.A.C.S., Associate Professor, Surgical Oncology, Emory University
  • “Y-90 Therapy in the Multidisciplinary Process” by Robert Martin II, M.D., Ph.D., Director, Division of Surgical Oncology, University of Louisville School of Medicine

About Selective Internal Radiation Therapy using SIR-Spheres microspheres

Selective Internal Radiation Therapy (SIRT), also known as radioembolization, is a proven technology for inoperable liver cancer that delivers doses of radiation directly to the site of tumors. In a minimally invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.

Clinical studies have confirmed that patients with metastatic colorectal cancer treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.

SIR-Spheres microspheres are approved for use in Australia, the United States of America (FDA PMA approval), the European Union (CE Mark), and Argentina (ANMAT). Additionally, SIR-Spheres microspheres are supplied in countries such as Hong Kong, Malaysia, Singapore, Thailand, Taiwan, India, Israel, and Turkey. Available at more than 600 treatment centers, over 25,000 doses of SIR-Spheres microspheres have been supplied worldwide.

For more information, visit www.sirtex.com.

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.

Copyright Business Wire 2010